VXRT - Vaxart's Oral Vaccine For Stomach Bug Shows Reduction In Infection Rate | Benzinga
Vaxart Inc (NASDAQ: VXRT) released topline data from the Phase 2 challenge study of its oral tablet monovalent norovirus vaccine candidate.
In July, the company released interim data.
Norovirus is a very contagious virus that causes vomiting and diarrhea. Anyone can get infected and sick with norovirus. Norovirus is sometimes called the "stomach flu" or "stomach bug.
The Phase 2 challenge study enrolled 165 healthy adults. Four weeks after vaccination, subjects were challenged with GI.1 norovirus.
The study achieved its primary endpoint of a ...